Search

Abstract Introduction and objective Migraine is a chronic paroxysmal neurological disease characterised by attacks of moderate to severe headache and accompanying symptoms such as hypersensitivity to light and sound and gastrointestinal disturbances such as nausea and vomiting, among others. In some people, an attack of pain is preceded by a migraine aura - visual disturbances, numbness, tingling and even muscle weakness. Treatment includes medications taken as a temporary measure (at the onset of an attack) and as a prophylactic measure. The aim of this study is to systemasise information about chronic migraine and to raise awareness about this disease among health care workers and patients Brief description of the state of knowledge Migraine is a recurrent, usually unilateral, throbbing headache. A migraine usually lasts between 4 and 72 hours. It is characterised by varying degrees of severity and frequency of occurrence. The pain is exacerbated by emotion or physical exertion. There is photophobia, hypersensitivity to sounds (phonophobia) and odours (osmophobia), and nausea and vomiting occur. Sometimes before a migraine episode occurs, a so-called aura - occurring in 10% of migraine cases may appear, in the form of paresthesias, visual field loss, appearance of gloom, paresis, aphasia. Chronic migraine is a headache that occurs for at least 15 days per month, at least 8 of which are days when the headache has the characteristics of migraine pain as described below or is relieved by prescription anti-migraine medication. There are many triggers for migraine, which include genetic, environmental and personal factors. Chronic migraine severely reduces the quality of life of affected patients, therefore it is important to raise awareness of currently available methods for its diagnosis and treatment

Stroke is a very serious life-threatening condition. It is the second cause of death worldwide [5], while even in non-fatal cases it can result in severe disability and complications [5, 8]. Of all cases, ischaemic stroke is the most common, accounting for 87% of all ischaemic stroke cases [4]. Some hope is offered by the fact that modifiable risk factors are responsible for 90% of ischaemic stroke cases [7, 14]. Consequently, a number of recommendations have been made regarding health-promoting behaviours and treatment goals for diseases associated with an increased risk of stroke in high-risk populations. The aim of this work is to present risk groups, i.e. patient groups at higher than population risk of stroke, and to assess the effectiveness of the recommendations and the impact of their application on stroke risk. Methods and materials We reviewed the literature available on PubMed and Google Scholar using the words: Stroke, ischemic stroke, prevention, epidemiology Summary The data analysed clearly indicate that modifiable risk factors are responsible for the majority of cases (up to 90%) of stroke. Identifying risk groups on the basis of the Life's Essential 8 proposed by the American Heart Association for the prevention of cardiovascular disease, yields measurable results in lowering the risk of stroke among patients. Clearly defined standards can also set therapeutic targets for the treatment of conditions and diseases strongly associated with stroke risk and further improve population health. Primary care plays a very important role, as it is often the patient's first contact with the health care system. Keywords: Stroke, ischemic stroke, prevention, epidemiology

Introduction Breast cancer is the most common malignancy in women in developed countries. It also occurs in men. The primary therapy for these cancers is surgery; chemotherapy, radiation therapy, hormone therapy, or immunotherapy are also used. More and better treatments are being sought for this disease. The use of PARP inhibitors in the treatment of breast cancer has shown good results, so in this article we have done a review of the results of various studies on this topic. [1] In this review, the results of studies on the use of various PARP inhibitors in breast cancer of different hormonal status are presented. Purpose This article aims to give you an overview of the trials that have looked at the effects of different PARP inhibitors in the treatment of breast cancer. PARP inhibitors are a relatively new cancer therapy with good results, so it is important to pay attention. State of Knowledge In this article, I used the PubMed database and considered papers from the last 15 years, but most of the information in this review comes from papers published after 2020. I have also taken into account the recommendations of the FDA and the European Medicines Agency on the use of PARP inhibitors. Conclusions PARP inhibitors have shown significant effects on breast cancer outcomes. The differences in outcomes depending on the type of cancer, the PARP inhibitor used, and the previous therapies used in a given patient tell us how important it is to individualize therapy in oncology. The findings of the studies presented in this review also point to the need for further research that could focus on identifying patients who may best benefit from treatment with PARP inhibitors, as well as studying synergistic effects in combination with other forms of therapy, such as immunotherapy or chemotherapy. The changes in treatment outcomes that these drugs can bring underscore the importance of exploring new therapeutic strategies in oncology.